Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 1CNS 1

Conditions

Leukemia 10Leukemia, Myeloid, Acute 7Congenital Abnormalities 6Glioblastoma 5Lung Neoplasms 4Leukemia, Myelomonocytic, Acute 4Leukemia, Monocytic, Acute 4Leukemia, Megakaryoblastic, Acute 4Leukemia, Erythroblastic, Acute 4Gliosarcoma 4Colorectal Neoplasms 4Central Nervous System Neoplasms 4Carcinoma, Non-Small-Cell Lung 4Wilms Tumor 3Uterine Cervical Neoplasms 3Squamous Intraepithelial Lesions 3Myelodysplastic Syndromes 3Colonic Neoplasms 3Carcinoma, Ovarian Epithelial 3Breast Neoplasms 3Sarcoma 2Rectal Neoplasms 2Precancerous Conditions 2Ovarian Neoplasms 2Oligodendroglioma 2Leukemia, Eosinophilic, Acute 2Leukemia, Basophilic, Acute 2Kidney Neoplasms 2Carcinoma, Intraductal, Noninfiltrating 2Brain Neoplasms 2

Interventions

Cabergoline 6Dopamine Agonists 2ropinirole 1pasireotide 1Tissue Banks 1Temozolomide 1Surgical Procedures, Operative 1Standard of Care 1Microarray Analysis 1Magnetic Resonance Spectroscopy 1Lapatinib 1Early Intervention, Educational 1Dexamethasone 1DNA Methylation 1Clomiphene 1Calcium Dobesilate 12,2-dimethyl-N-(6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-N'-(2,2,3,3,3-pentafluoropropyl)malonamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Prolactinoma × DNA Methylation × Clear all
NCT00601289 2020-07-31

Temozolomide in Treating Patients With Invasive Pituitary Tumors

Jonsson Comprehensive Cancer Center

Phase 2 Withdrawn
CNSEndocrine

Adenoma, Basophil, Adenoma, Chromophobe, Adenoma, Acidophil, Pituitary Neoplasms, Prolactinoma, Central Nervous System Neoplasms, Growth Hormone-Secreting Pituitary Adenoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡